Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study
Patients with NSCLC experiencing tumor progression post-immunotherapy can still benefit from further treatment, with immunotherapy combined with antiangiogenic therapy the most efficacious option.
Authors
- Junfeng Zhao (ORCID: https://orcid.org/0000-0003-4843-4871)
- Ruidan Zhang (ORCID: https://orcid.org/0000-0002-9582-1869)
- Yintao Li (ORCID: https://orcid.org/0000-0003-4665-8900)
- Xue Dong (ORCID: https://orcid.org/0000-0002-3355-7476)
- Ying Li (ORCID: https://orcid.org/0000-0003-2136-0673)
- Ruyue Li (ORCID: https://orcid.org/0009-0006-2086-4131)
- Xiujing Yao (ORCID: https://orcid.org/0009-0006-8420-9814)
Institutions
- Weifang Medical University (CN)
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Neoplasia
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1016/j.neo.2024.101043
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- National Natural Science Foundation of China